JOURNAL OF DRUG TARGETING

metrics 2024

Connecting researchers to the forefront of drug delivery science.

Introduction

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Metrics 2024

SCIMAGO Journal Rank0.85
Journal Impact Factor4.30
Journal Impact Factor (5 years)4.60
H-Index107
Journal IF Without Self4.30
Eigen Factor0.00
Normal Eigen Factor0.63
Influence0.73
Immediacy Index0.60
Cited Half Life7.00
Citing Half Life5.70
JCI0.94
Total Documents1999
WOS Total Citations5066
SCIMAGO Total Citations19207
SCIMAGO SELF Citations561
Scopus Journal Rank0.85
Cites / Document (2 Years)5.36
Cites / Document (3 Years)4.87
Cites / Document (4 Years)5.06

Metrics History

Rank 2024

Scopus

Pharmaceutical Science in Pharmacology, Toxicology and Pharmaceutics
Rank #23/183
Percentile 87.43
Quartile Q1

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 69/354
Percentile 80.60
Quartile Q1

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 94/354
Percentile 73.45
Quartile Q2

Quartile History

Similar Journals

Advanced NanoBiomed Research

Uniting Engineering and Medicine for Breakthroughs
Publisher: WILEY-V C H VERLAG GMBHISSN: 2699-9307Frequency: 12 issues/year

Advanced NanoBiomed Research is a pioneering open-access journal committed to advancing the interdisciplinary field of nanobiotechnology, published by WILEY-V C H VERLAG GMBH. Since its inception in 2021, this journal has provided a platform for innovative research that bridges the gap between engineering, medicine, and materials science. With impressive rankings in Scopus, positioning it within the top quartiles of various categories, Advanced NanoBiomed Research aims to disseminate high-quality research that contributes to the understanding and application of nanomaterials in biomedical contexts. As it encompasses a wide scope—from applied microbiology to biomaterials—it serves as an essential resource for researchers, professionals, and students eager to explore the cutting-edge developments in the field. The journal promotes a collaborative environment where emerging ideas can flourish, ensuring that vital advancements in nanobiomedicine can be shared and built upon within the scientific community.

Theranostics

Pioneering Multidisciplinary Approaches in Healthcare.
Publisher: IVYSPRING INT PUBLISSN: 1838-7640Frequency: 1 issue/year

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

Expert Opinion on Drug Delivery

Catalyzing Progress in Pharmacology and Pharmaceutics
Publisher: TAYLOR & FRANCIS LTDISSN: 1742-5247Frequency: 12 issues/year

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Advanced Pharmaceutical Bulletin

Unveiling Innovative Discoveries in Pharmacology and Toxicology
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5881Frequency: 2 issues/year

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

Materials Science & Engineering C-Materials for Biological Applications

Transforming health through cutting-edge material solutions.
Publisher: ELSEVIERISSN: 0928-4931Frequency: 12 issues/year

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Biomaterials Research

Exploring new horizons in biomaterials science.
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: 1226-4601Frequency: 1 issue/year

Biomaterials Research, published by the American Association for the Advancement of Science, is a prominent open access journal established in 2014, dedicated to advancing the field of biomaterials. Based in the United Kingdom, this journal has swiftly become an essential platform for researchers and practitioners, offering groundbreaking insights in biomaterials, biomedical engineering, ceramics and composites, and miscellaneous medical fields. With its impressive Q1 ranking across multiple relevant categories in 2023 and its strong Scopus rankings, including a remarkable 90th percentile in the medicine category, Biomaterials Research showcases high-quality, peer-reviewed research designed to address both practical and theoretical challenges in biomaterials science. As an open access journal, it promotes wider dissemination and accessibility of research findings, crucial for fostering innovation and collaboration within the scientific community. Researchers, professionals, and students alike are encouraged to contribute, read, and engage with the latest developments in this dynamic field.

Biomaterials Science

Uniting academia and industry to revolutionize biomaterials science.
Publisher: ROYAL SOC CHEMISTRYISSN: 2047-4830Frequency: 24 issues/year

Biomaterials Science is a premier journal published by the Royal Society of Chemistry that serves as a leading platform for researchers and professionals in the fields of Biomedical Engineering and Materials Science. With an impressive impact factor bolstered by its Q1 quartile ranking in both disciplines, this journal has positioned itself at the forefront of cutting-edge research, showcasing innovative materials and applications that drive advancements in healthcare and technology. Since its inception in 2013, Biomaterials Science has been committed to disseminating high-quality, peer-reviewed articles that promote scientific knowledge and collaboration among academia and industry. With a global readership and a focus on open access, researchers are encouraged to share their findings to facilitate the development of transformative biomaterials and their applications. Join a vibrant community of scholars as we explore the future of biomaterials through this esteemed publication, enhancing both scientific inquiry and practical application.

DRUG DELIVERY

Connecting Ideas, Advancing Medicine
Publisher: TAYLOR & FRANCIS LTDISSN: 1071-7544Frequency: 1 issue/year

DRUG DELIVERY is a premier academic journal published by TAYLOR & FRANCIS LTD, with a steadfast commitment to advancing research in the fields of medicine and pharmaceutical sciences. As an Open Access journal since 2017, it offers unparalleled accessibility to its high-quality content, making it an invaluable resource for researchers, professionals, and students alike. With an impressive 2023 impact factor, it ranks in the Q1 quartile for both Medicine (miscellaneous) and Pharmaceutical Science, evidencing its significant impact within the scientific community. The journal focuses on innovative drug delivery systems, therapeutics, and methodologies that enhance patient care and treatment options. Based in the United Kingdom, it has evolved since its inception in 1993 to create a richly diverse platform for scholarly dialogue and advancements in the pharmaceutical landscape. Researchers looking to stay at the forefront of drug delivery research will find DRUG DELIVERY an essential companion in their pursuits.

Cancer Nanotechnology

Unlocking the Potential of Nanotechnology in Oncology
Publisher: SPRINGER WIENISSN: 1868-6958Frequency: 1 issue/year

Cancer Nanotechnology is a cutting-edge peer-reviewed journal dedicated to advancing the field of cancer research through innovative nanotechnology applications. Published by SPRINGER WIEN, this open-access journal, established in 2010, provides a vital platform for the dissemination of high-quality research with a focus on the intersection of nanotechnology, oncology, and biomedical engineering. With a commitment to promoting accessibility and fostering collaboration, Cancer Nanotechnology has gained impressive rankings within specialized categories, including Q2 in Biomedical Engineering and Pharmaceutical Science. The journal's rigorous selection process ensures that only the most impactful studies reach its audience, making it a must-read for researchers, professionals, and students eager to explore the latest advancements and methodologies in cancer treatment. With its scope encompassing critical topics that bridge multiple disciplines—including physical chemistry and toxicology—Cancer Nanotechnology positions itself as an influential resource for shaping the future of cancer therapies.

BioChip Journal

Pioneering Research at the Intersection of Bioengineering and Technology
Publisher: KOREAN BIOCHIP SOCIETY-KBCSISSN: 1976-0280Frequency: 4 issues/year

BioChip Journal, published by the Korean Biochip Society (KBCS), is a renowned academic platform dedicated to advancing the fields of bioengineering, biomedical engineering, biotechnology, and electrical and electronic engineering. With its ISSN 1976-0280 and E-ISSN 2092-7843, this esteemed journal has established itself as a valuable resource for researchers, professionals, and students alike, providing them with cutting-edge research and insights since its inception in 2008. The journal has earned a commendable standing in the academic community, achieving Q2 ranking across key categories, thereby placing it amongst the top-tier publications. With its impressive Scopus rankings, including a top 10% position in Electrical and Electronic Engineering and a strong showing in both Biomedical Engineering and Biotechnology, BioChip Journal plays a vital role in disseminating innovative biochip technologies and applications. The journal continues to invite groundbreaking studies and reviews that promote the interdisciplinary collaboration essential for the future of biochip research, ultimately contributing to advancements in healthcare, diagnostics, and therapeutics.